LOGIN  |  REGISTER

Haemonetics 2nd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website

November 02, 2023 | Last Trade: US$76.90 1.87 -2.37

BOSTON, Nov. 2, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2024, which ended September 30, 2023, are available on its Investor Relations website.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on November 2, 2023. The conference call and webcast can be accessed with the following information:

  • Teleconference link
  • Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
  • A live webcast of the call can be accessed on Haemonetics' investor relations website or via the following link: https://edge.media-server.com/mmc/p/twgnwbaw

In addition, the Company has posted to its Investor Relations website the earnings release that will be referenced on its conference call and webcast, a link to which is available below.  

Direct link to 2Q FY24 Earnings Release

A replay of the conference call and webcast will be available for one year beginning on November 2, 2023, at 11:00 a.m. ET using the conference call webcast link provided in this press release.

ABOUT HAEMONETICS

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:             

 

Olga Guyette, Sr. Director-Investor Relations & Treasury  

David Trenk, Manager-Investor Relations

(781) 356-9763                                                                       

(203) 733-4987

This email address is being protected from spambots. You need JavaScript enabled to view it.                                            

This email address is being protected from spambots. You need JavaScript enabled to view it.                                                                                 

Media Contact:          

 

Josh Gitelson, Director-Global Communications

 

(781) 356-9776

 

This email address is being protected from spambots. You need JavaScript enabled to view it. 

 

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB